Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BULLISH HAMMER
Definition
This pattern occurs at the bottom of a trend or during a downtrend and it is called a Hammer since it is hammering out of a bottom. It is a single candlestick pattern that has a long lower shadow and a small body at or very near the top of its daily trading range.
Recognition Criteria
1. The market is characterized by a prevailing downtrend.
2. A small body at the upper end of the trading range is observed. The color of the body is not important.
3. The lower shadow of this candlestick is at least twice as long as the body.
4. There is (almost) no upper shadow.
Pattern Requirements and Flexibility
The body of the Hammer should be small. The lower shadow should be at least twice as long as the body, but not shorter than an average candlestick. It is desired that there is no or a very tiny upper shadow. The bottom of the Hammer’s body should be lower than both of the two preceding black candlesticks.
Trader’s Behavior
The Bullish Hammer appears in a downtrend and it sells off sharply following the market open. After the decline ceases, the market almost returns to the high of the day. Apparently the market fails to continue on the selling side. This observation reduces the previous bearish sentiment causing short traders to feel increasingly uneasy with their bearish positions. If the body of the Hammer is white, then the situation looks even better for the bulls.
Buy/Stop Loss Levels
The confirmation level is defined as the top of the Hammer’s body. Prices should cross above this level for confirmation.
The stop loss level is defined as the last low. Following the BUY, if prices go down instead of going up, and close or make two consecutive daily lows below the stop loss level, while no bearish pattern is detected, then the stop loss is triggered.
Trading the Bullish Hammer Candle
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
NEW YORK, NY--(Marketwired - Jun 26, 2014) - Plandaí Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare™ Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
The company's Vice President of Sales Callum Baylis-Duffield said of the exemption, "As we gear up to commence marketing Phytofare™ in the coming quarter, qualifying for this exemption is a huge milestone. Had we been forced to apply to the FDA, the cost in terms of time, opportunity and hard dollars spent would have been tremendous."
And, he's right. The exemption is great news for investors who have been eagerly anticipating Plandaí getting its first product into the market, and now with the third quarter just days away, the company is entering truly exciting times. Plandaí's long awaited Phytofare™ Catechin Complex is the realization of a great deal of hard work, planning and company expertise. It is that expertise that has garnered Plandaí the exemption that will save it a lot of time and money.
The product which includes the entire Catechin profile derived from live green tea that is grown and processed on the Company's 30,000 square foot factory located on its Senteeko estate in South Africa qualifies for the exemption because it has been present in the food supply without being chemically altered -- all thanks to Plandaí's proprietary extraction process.
It is that process that led to the legal opinion letter that the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, delivered stating that Plandaí will not be required to apply to the FDA for approval to market and sell its Phytofare™ Catechin Complex.
The Dietary Supplement Health and Education Act of 1994 makes it clear that a number of "physical modifications" like those undertaken in Plandaí's extraction and processing do not constitute "chemical alteration."
Plandaí's VP of Sales says, "Having a firm with the reputation and standing of Hyman, Phelps & McNamara issue us this opinion gives us ideal positioning within the marketplace and enables our distributors to immediately commence marketing the product in the US and abroad."
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí content by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. To date, SMMG has received total compensation of $52,670 for content related to Plandaí. For more information: www.stockmarketmediagroup.com.
Contact:
Stock Market Media Group
Email Contact
Source: Marketwired (June 26, 2014 - 9:00 AM EDT)
As you can see now from todays open I am correct when I asserted to be cautious today.
Word of caution. This news was known to us yesterday and it ran up. Then this morning it tanked. The MM's kept it in a channel between .55-.58 till 2:30 p.m. and then released it but it didn't take on any buyers above .59 and then it began to tank below .58 as those same buyers, not MM's, saw that it had no legs. The news out @ 4:01 p.m. was strategic. Remember the reason we sell the news and this is essentially old news, just confirmed a day later.
Go TRTC & GL
I would like to point out that the CBD component of HEMP or cannabis is being evaluated by the folks a GWP- and as of yesterday mornings PR the stock gapped up on positive resulting CBD news in phase study. The resulting internal phase studies at GW Pharma are a bonus for all CBD oriented marijuana sector stocks. The plus is that a giant pharma is doing all the leg work for the community sector involved in the CBD benefits. A real bonus. HANG ON TIGHT. MJNA
So sad. Reputation of the management involved with MJNA will be
"mud". All the promises of a bright future just a bunch of hype. Now the industry is growing by leaps and bounds. FED is getting out of the way slowly but surely. MJNA appears to have an impressive portfolio of subsidiary holdings, yet the company doesn't really have any numbers by which it can stand on its own two feet. Spin it any way you want, this company doesn't have legs to walk let alone run and it appears it may fall flat on its keester before it goes up. So sad.
Can you see why I'm reluctant to believe anything you say:
MJNA short value for 9/17/13 = (22.86%) 932,215 shrs lowest in a long time
MJNA short value for 9/16/13 = (22.58%) 1,183,589 shrs
MJNA short value for 9/13/13 = (28.46%) 1,702,089 shrs
MJNA short value for 9/12/13 = (25.54%) 1,191,665 shrs
MJNA short value for 9/11/13 = (22.27%) 2,507,280 shrs
MJNA short value for 9/10/13 = (33.28%) 6,756,576 shrs
MJNA short value for 9/9/13 = (34.30%) 5,197,435 shrs
MJNA short value for 9/6/13 = (40.08%) 4,710,090 shrs
MJNA short value for 9/5/13 = (22.22%) 2,864,849 shrs
Comparing the charts to the % short you will notice that on the highest short days the following day brings on a squeeze by the one and only VNDM. The only other time the shorts are around is the day after a spike/pump/dump.
This ticker is controlled by an MM. I believe the primary is VMDN. Right now support is kept @ .16 with dumps pushing it to a buyin @ .1575 for the past week. It is safe to say they will not let it breech support or a lower low of .10 for a single day as that would impede the desired up listing, unless they want it to breech that support to intentionally slow down the up listing. At this point there is a controlled uptrend taking shape and only positive news will cause the MM to move aside long enough to let it run/peak and then start feeding at the trough to bring it to a higher low. GLTA
READ AND WEED TIME Form 10-Q for MEDISWIPE INC.
14-Aug-2013
Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
The following is management's discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words "believes," "anticipates," "may," "will," "should," "expect," "intend," "estimate," "continue," and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited consolidated financial statements and notes thereto for the years ended December 31, 2012 and 2011, included in our annual report on Form 10-K filed with the SEC on April 13, 2013.
The independent auditors reports on our financial statements for the years ended December 31, 2012 and 2011 includes a "going concern" explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. Management's plans in regard to the factors prompting the explanatory paragraph are discussed below and also in Note 11 to the condensed consolidated financial statements filed herein.
(a) Liquidity and Capital Resources.
For the six months ended June 30, 2013, net cash used in operating activities was $151,505 compared to $29,577 for the six months ended June 30, 2012. The company had a net loss $3,600,137 for the six months ended June 30, 2013 compared to a net loss of $83,529 for the six months ended June 30, 2012. The net loss for the six months ended June 30, 2013 was impacted by stock and warrant compensation expense of $3,221,015 comprised of $2,821,275 of preferred stock compensation, the amortization of deferred stock compensation of $170,265 from the previous issuance of Series B preferred stock, $124,200 warrant based compensation for the issuance of a warrant to purchase 3,000,000 shares of common stock to our advisor to the board of directors, $80,000 for the one time issuance of 2,000,000 shares of common stock to the same advisor, 250,000 shares of common stock (with an additional 250,000 shares to be issued each quarter the advisor continues his relationship with the Company) valued at $9,775 and $15,500 for the issuance of 250,000 shares for services provided to the Company. Additional non-cash expenses for the six months ended June 30, 2013 were the amortization of the initial discounts of $61,998 on the convertible notes, the initial derivative liability expense and the change in the fair value of the derivatives of $30,293, amortization of deferred financing fees of $13,916 also related to the convertible promissory notes and a beneficial conversion feature related to the conversion of the contingent liability to common stock of $29,561.
During the six months ended June 30, 2013, net cash provided by financing activity was $266,500. This was comprised of issuance of convertible promissory notes of $92,500, proceeds of $200,000 related to the Typenex convertible note
(see note 6 to the condensed consolidated financial statements contained herein)
and the payment of deferred financing fees of $26,000.
For the six months ended June 30, 2013, cash and cash equivalents increased by $114,995 compared to a decrease of $2,577 for the six months ended June 30, 2012. Ending cash and cash equivalents at June 30, 2013 was $116,887 compared to $1,892 at December 31, 2012.
We have limited cash and cash equivalents on hand. We presently maintain our daily operations and capital needs through the sale of our products. We will need to raise funds to continue to be able to support our operating expenses and to meet our other obligations as they become due. Sources available to us that we may utilize include the sale of unsecured convertible debentures from unaffiliated investors which may cause dilution to our stockholders. The company expects to increase sales of additional products over the course of this fiscal year.
(b) Results of Operations
Results of operations for the three and six months ended June 30, 2013 vs. June 30, 2012
REVENUES
During the three and six months ended June 30, 2013, the Company's revenues were $38,267 and $88,065, respectively, compared to $23,334 and $49,458 for the three and six months ended June 30, 2012, respectively. The revenues for the six months ended June 30, 2013, were comprised of $49,818 from Alternative Capital Solutions ("ACS"), $30,354 from our sales of our Chillo and C+ Swiss products and $7,914 related to our Cloud based products. In April 2013, ACS and the Company terminated their agreements and accordingly, the Company will no longer be receiving fees related to the ACS agreement. The Company recently entered into an exclusive distributorship agreement with Chill Drinks, LLC (See Note 1) for sales of Chill Drink's products to dispensaries. Sales began in April 2013. Also during the quarter ending June 30, 2013 the Company generated revenues related to its' patient software (See note 1) and anticipates to begin a monthly recurring revenue model, whereby dispensaries will pay up to $400 per month for access to Cloud based software. Additionally through Cloud based software, the Company will be selling a patient digital health record storage system for an annual fee. The Company will be introducing additional products in the forthcoming quarters to supplement the initial products.
Revenues from 2012 period were all related to merchant processing fees the Company received from medical dispensaries. Effective July 1, 2012, the merchant processing fees ceased as a result of Mastercard and Visa declining to accept credit card charges from medical dispensaries.
OPERATING EXPENSES
Operating expenses were $3,247,517 and $3,511,000 for the three and six months ended June 30, 2013, compared to $67,104 and $121,426 for the three and six months ended June 30, 2012.
Administration and management fees increased as a result of the increase of the amount accrued for the salaries for our CEO from $22,500 for the three and six months ended June 30, 2012 to $37,500 and $75,000 for the three and six months ended June 30, 2013, compensation recorded for our CFO of $24,000 and $48,000 for the three and six months ended June 30, 2013.
Stock compensation expense, management was comprised of $2,821,275 of preferred stock compensation, $124,200 warrant based compensation for the issuance of a warrant to purchase 3,000,000 shares of common stock to our advisor to the board of directors, $80,000 for the one time issuance of 2,000,000 shares of common stock to the same advisor, 250,000 shares of common stock (with an additional 250,000 shares to be issued each quarter the advisor continues his relationship with the Company) valued at $9,775. Stock compensation expense, other includes the amortization of deferred stock compensation of $170,265 from the previous issuance of Series B preferred stock and $15,500 for the issuance of 250,000 shares for services provided to the Company.
Professional and consulting fees increased for the three and six month periods in 2013 compared to 2012 as a result of investor relation costs of $8,094 and $22,396 for the three and six months ended June 30, 2013, respectively, compared to $2,650 and $6,200 for the three and six months ended June 30, 2012, respectively. Consulting fees of $4,500 and $19,200 were incurred for the three nd six months ended June 30, 2013, respectively of which $16,700 was pursuant to the ACS agreement. Commissions of $31,200 were also incurred for the six months ended June 30, 2013pursuant to the ACS Agreement.
General and other administrative costs for the three and six months ended June 30, 2013, were $21,029 and $47,080, respectively, compared to $21,029 and $33,043 for the three and six months ended June 30, 2012, respectively. Expenses for the six months ended June 30, 2013, include public company filing fees of $14,141, travel and entertainment costs of $11,547, internet and web based service costs of $8,386, certification station set up costs of $2,904 and $10,102 of other general and administrative costs.
OTHER INCOME (EXPENSE)
Other expense for the three and six months ended June 30, 2013 was $117,830 and $152,853, respectively, compared to $10,844 and $12,256 for the three and six months ended June 30, 2012. Included in the current period is interest expense of $63,069 (three months) and $92,999 (six months), comprised of $36,674 (three months) and $61,998 (six months) related to the amortization of the initial discount on convertible promissory notes, $14,685 (three months) and $16,085 (six months) for the amortization of the deferred financing costs and $11,710 (three months) and $14,196 (six months) for the interest expense on the face value of the notes. Also included in other expenses for the six months ended June 30, 2013 was $17,210 for the initial derivative liability expense for the embedded derivative in newly issued convertible notes and an expense of $13,083 for the fair value change on the derivative liability associated with the convertible promissory notes. Other expenses for the three and six months ended June 30, 2012 included interest expense of $46,812 (three months and $92,936 (six months). Interest expense was comprised of $41,477 (three months) and $81,806 (six months) related to the amortization of the initial discount on convertible promissory notes, $2,719 (three months) and $5,526 (six months) for the amortization of the deferred financing costs and $2,596 (three months) and $5,584 (six months) for the interest expense on the face value of the notes. For the three months ended June 30, 2012 the fair value change in the derivative associated with convertible promissory notes resulted in an expense of $26,668 and for the six months ended June 30, 2012, expenses were partially offset for the fair value change (decrease) of $18,044 in the derivative liability associated with convertible promissory notes.
OFF BALANCE SHEET ARRANGEMENTS
None
Critical Accounting Policies
See Note 2 to the condensed consolidated financial statements included herein.
Here is the straight skinny on MJNA:
1. It will find its way back to .12-.13 where it recently rested.
2. It is doubtful price will drop below .10 but should it, it will always close over .10 so that the up-listing isn't delayed more than necessary.
3. Small chance revenues next quarter could give us a higher stable pps. Incremental growth is now the normal.
With the exception of an up listing rocketing it into orbit, MJNA pps will increase based on the organics of the company, with the exception of a buy out. Long term investment.
Sanjay Gupta set stage for Eric Holder to Announce Major Criminal Law Reforms on Today. It's About Time this Administration Caught Up with the States.
By Chloe Cockburn, Advocacy and Policy Counsel, ACLU & Alex Stamm, ACLU Center for Justice at 3:58pm
Today, Monday, Eric Holder will give a speech that we expect to propose some major policy shifts in the federal sentencing and enforcement arena. As NPR reported this week, Holder's position is that "there are too many people in jail for too long, and for not necessarily good reasons." We could not agree more. Moreover, given the wave of criminal justice reforms we have seen cropping up in states around the country, now is the right time for the administration to get with the program and show some leadership in rolling back some pretty disastrous policies.
Over the past few years, state lawmakers have grown increasingly disenchanted with the results of extreme sentencing laws and broad criminalization of conduct instituted in the 1980's and 1990's. These results include 2.3 million people in prisons and jails, the fact that 1 in 4 adults now has a serious misdemeanor or felony on their record making it difficult to secure employment and housing, and the mind boggling price tag of over $70 billion dollars a year (not counting collateral costs).
During the recently-ended 2013 legislative session (see here for a session calendar), lawmakers took modest, promising steps to extract us from the mass incarceration trap. Here are the highlights:
MARIJUANA LAW REFORM
As we observed earlier this year, this is one of the strongest trends in criminal justice reform. The public, policy makers, and opinion makers are growing increasingly averse to senselessly punitive enforcement of marijuana laws. CNN's Dr. Sanjay Gupta's recent reversal of his previously hostile stance against marijuana is the most recent high-profile about-face in this arena. State lawmakers are taking cues: marijuana reform bills were introduced in 30 states this session. Below are some of the most impressive developments.
Washington and Colorado set the tone for the session with historic marijuana legalization initiatives that passed last fall. The passage of these measures with strong public support gave a boost to the long-term efforts of advocates in other states pushing for more sensible policies. Meanwhile, as progress unfolds elsewhere, advocates are holding their breath as Colorado and Washington begin the complex task of implementing large new regulatory schemes under the shadow of an ambivalent federal position.
In Vermont, where support for marijuana reform became a major campaign issue in the Attorney General race, the legislature passed a decriminalization bill (where possession remains unlawful but punishable only by a civil fine) by a large majority. Decriminalization bills in Hawaii, Maryland, New Hampshire, and New Mexico each passed one legislative chamber and are likely to return next year. A New York bill to eliminate the "public view" exception to the state's decriminalization law, which the NYPD has notoriously exploited by commanding people to empty their pockets during police stops and then arresting them for displaying marijuana in public, made it through the Assembly but not the Senate. A recently-introduced decriminalization bill in the District of Columbia was co-sponsored by a majority of City Council members and stands a strong chance of passing this fall.
Illinois, Maryland, and New Hampshire each legalized marijuana for medical use, which brings the total number of medical marijuana states to 20, as well as D.C. (which just opened its first dispensary after years of foot dragging by the Mayor's office). Medical marijuana bills were introduced 16 other states; you can find more details about all of these bills at the Marijuana Policy Project's website.
OTHER DRUG LAW REFORM
Criminal justice trend-setter Colorado passed SB 250, a complete rewrite of the state's Controlled Substances Act (summary here). The bill creates a new drug classification and sentencing grid with reduced penalties, raises the threshold amounts that trigger higher penalties, allows felony drug convictions to be reduced to misdemeanors under certain conditions, and more. An analysis of the bill estimates that the bill could reduce prison admissions by five percent or more.
California's Senate passed SB 649, a "wobbler" bill giving prosecutors the discretion to charge any drug possession as a misdemeanor rather than a felony; the Assembly takes up the bill this fall. If the bill passes, California will join 13 other states and the District of Columbia in allowing misdemeanor charging in all drug possession cases. Alaska's Senate passed a bill to make possession of some drugs misdemeanors in all cases, but the House did not approve it.
And Louisiana passed Governor Jindal's bill to divert some defendants from prison and allow some prisoners to earn sentence reductions if they complete a drug treatment program.
MANDATORY MINIMUM SENTENCING REFORM
Oregon advocates set their sights high this year with a bid to repeal mandatory minimums for Robbery II, Assault II, and Sexual Abuse I, which have become major incarceration drivers in the state. In the face of fierce opposition from district attorneys, bill supporters gave up the mandatory minimum reforms to ensure passage of the rest of the bill, which included modest drug and property crime reform while emphasizing community corrections (HB 3194), and is projected to avert future prison growth and costs.
Efforts to eliminate mandatory sentences for certain drug offenses were introduced in Florida, Louisiana, North Carolina and South Carolina, but did not pass. A bill still pending in Massachusetts would repeal mandatory minimum sentences for all nonviolent drug offenses.
Short of repeal, several states have taken up "safety valve" measures allowing judges to depart from mandatory minimums in special cases. Hawaii passed SB 68, creating a safety valve for certain lower-level felonies. Georgia passed HB 349, which creates a very limited safety valve for drug and other offenses. The recent publication by ALEC of a model safety valve bill for the states signals that we will see many more reforms like this next year.
OTHER SENTENCING REFORMS
Indiana overhauled its criminal code. The bill creates a new set of felony sentencing tiers, which if applied to felony convictions from 2008-2012 would have lowered the sentence range for over 80% of defendants. Hundreds of people would have been convicted of a misdemeanor instead of a felony. Missouri lawmakers introduced a similar code reform bill, which passed one chamber and could be revived next year.
More notable reforms this session included: amendments to felony theft thresholds (Colorado and Maryland), parole reforms (South Dakota, Kansas and West Virginia), pretrial diversion (Colorado and Alabama), and reducing felonies to misdemeanors after good behavior (Texas, Colorado). Michigan passed a substantial indigent defense reform bill.
FEDERAL SENTENCING REFORMS
This year's federal legislation has been particularly encouraging. Most notable is the Justice Safety Valve Act of 2013, which would allow federal judges to sentence defendants below the mandatory minimums in some cases. Introduced by Sens. Leahy (D-VT) and Paul (R-KY), the bill has attracted broad support, including The New York Times, Grover Norquist, and a group of 50 former prosecutors.
Additionally, last week saw the release of the Smarter Sentencing Act of 2013, which would reduce some federal mandatory minimum sentences, make a modest expansion to the safety valve provision (though continuing to exclude anyone previously incarcerated in prison for more than 13 months in the past 10 years), and make the 2010 Fair Sentencing Act applicable to persons sentenced before its enactment, which would reduce sentences for people convicted of crack cocaine offenses.
THE BOTTOM LINE
A significant percentage of policy makers are reaching a consensus that our system of criminal penalties is inefficient, ineffective, and destructive and are supporting bills to change that. The results of some past reforms are bearing fruit: 2012 was the third straight year that the total number of prisoners in the U.S. decreased, shaving 27,770 prisoners off the 2011 total of 1.59 million. But few states have attempted to tackle reforms on a scale that matches the magnitude of the problem. Eric Holder has the opportunity to show some needed leadership on Monday. We hope his speech includes concrete plans for reforms that will push the envelope.
Eric Holder to Announce Major Criminal Law Reforms on Monday. It's About Time this Administration Caught Up with the States.
08/09/2013 Eric Holder to Announce Major Criminal Law Reforms on Monday. It's About Time this Administration Caught Up with the States.
By Chloe Cockburn, Advocacy and Policy Counsel, ACLU & Alex Stamm, ACLU Center for Justice at 3:58pm
Next Monday, Eric Holder will give a speech that we expect to propose some major policy shifts in the federal sentencing and enforcement arena. As NPR reported this week, Holder's position is that "there are too many people in jail for too long, and for not necessarily good reasons." We could not agree more. Moreover, given the wave of criminal justice reforms we have seen cropping up in states around the country, now is the right time for the administration to get with the program and show some leadership in rolling back some pretty disastrous policies.
Over the past few years, state lawmakers have grown increasingly disenchanted with the results of extreme sentencing laws and broad criminalization of conduct instituted in the 1980's and 1990's. These results include 2.3 million people in prisons and jails, the fact that 1 in 4 adults now has a serious misdemeanor or felony on their record making it difficult to secure employment and housing, and the mind boggling price tag of over $70 billion dollars a year (not counting collateral costs).
During the recently-ended 2013 legislative session (see here for a session calendar), lawmakers took modest, promising steps to extract us from the mass incarceration trap. Here are the highlights:
MARIJUANA LAW REFORM
As we observed earlier this year, this is one of the strongest trends in criminal justice reform. The public, policy makers, and opinion makers are growing increasingly averse to senselessly punitive enforcement of marijuana laws. CNN's Dr. Sanjay Gupta's recent reversal of his previously hostile stance against marijuana is the most recent high-profile about-face in this arena. State lawmakers are taking cues: marijuana reform bills were introduced in 30 states this session. Below are some of the most impressive developments.
Washington and Colorado set the tone for the session with historic marijuana legalization initiatives that passed last fall. The passage of these measures with strong public support gave a boost to the long-term efforts of advocates in other states pushing for more sensible policies. Meanwhile, as progress unfolds elsewhere, advocates are holding their breath as Colorado and Washington begin the complex task of implementing large new regulatory schemes under the shadow of an ambivalent federal position.
In Vermont, where support for marijuana reform became a major campaign issue in the Attorney General race, the legislature passed a decriminalization bill (where possession remains unlawful but punishable only by a civil fine) by a large majority. Decriminalization bills in Hawaii, Maryland, New Hampshire, and New Mexico each passed one legislative chamber and are likely to return next year. A New York bill to eliminate the "public view" exception to the state's decriminalization law, which the NYPD has notoriously exploited by commanding people to empty their pockets during police stops and then arresting them for displaying marijuana in public, made it through the Assembly but not the Senate. A recently-introduced decriminalization bill in the District of Columbia was co-sponsored by a majority of City Council members and stands a strong chance of passing this fall.
Illinois, Maryland, and New Hampshire each legalized marijuana for medical use, which brings the total number of medical marijuana states to 20, as well as D.C. (which just opened its first dispensary after years of foot dragging by the Mayor's office). Medical marijuana bills were introduced 16 other states; you can find more details about all of these bills at the Marijuana Policy Project's website.
OTHER DRUG LAW REFORM
Criminal justice trend-setter Colorado passed SB 250, a complete rewrite of the state's Controlled Substances Act (summary here). The bill creates a new drug classification and sentencing grid with reduced penalties, raises the threshold amounts that trigger higher penalties, allows felony drug convictions to be reduced to misdemeanors under certain conditions, and more. An analysis of the bill estimates that the bill could reduce prison admissions by five percent or more.
California's Senate passed SB 649, a "wobbler" bill giving prosecutors the discretion to charge any drug possession as a misdemeanor rather than a felony; the Assembly takes up the bill this fall. If the bill passes, California will join 13 other states and the District of Columbia in allowing misdemeanor charging in all drug possession cases. Alaska's Senate passed a bill to make possession of some drugs misdemeanors in all cases, but the House did not approve it.
And Louisiana passed Governor Jindal's bill to divert some defendants from prison and allow some prisoners to earn sentence reductions if they complete a drug treatment program.
MANDATORY MINIMUM SENTENCING REFORM
Oregon advocates set their sights high this year with a bid to repeal mandatory minimums for Robbery II, Assault II, and Sexual Abuse I, which have become major incarceration drivers in the state. In the face of fierce opposition from district attorneys, bill supporters gave up the mandatory minimum reforms to ensure passage of the rest of the bill, which included modest drug and property crime reform while emphasizing community corrections (HB 3194), and is projected to avert future prison growth and costs.
Efforts to eliminate mandatory sentences for certain drug offenses were introduced in Florida, Louisiana, North Carolina and South Carolina, but did not pass. A bill still pending in Massachusetts would repeal mandatory minimum sentences for all nonviolent drug offenses.
Short of repeal, several states have taken up "safety valve" measures allowing judges to depart from mandatory minimums in special cases. Hawaii passed SB 68, creating a safety valve for certain lower-level felonies. Georgia passed HB 349, which creates a very limited safety valve for drug and other offenses. The recent publication by ALEC of a model safety valve bill for the states signals that we will see many more reforms like this next year.
OTHER SENTENCING REFORMS
Indiana overhauled its criminal code. The bill creates a new set of felony sentencing tiers, which if applied to felony convictions from 2008-2012 would have lowered the sentence range for over 80% of defendants. Hundreds of people would have been convicted of a misdemeanor instead of a felony. Missouri lawmakers introduced a similar code reform bill, which passed one chamber and could be revived next year.
More notable reforms this session included: amendments to felony theft thresholds (Colorado and Maryland), parole reforms (South Dakota, Kansas and West Virginia), pretrial diversion (Colorado and Alabama), and reducing felonies to misdemeanors after good behavior (Texas, Colorado). Michigan passed a substantial indigent defense reform bill.
FEDERAL SENTENCING REFORMS
This year's federal legislation has been particularly encouraging. Most notable is the Justice Safety Valve Act of 2013, which would allow federal judges to sentence defendants below the mandatory minimums in some cases. Introduced by Sens. Leahy (D-VT) and Paul (R-KY), the bill has attracted broad support, including The New York Times, Grover Norquist, and a group of 50 former prosecutors.
Additionally, last week saw the release of the Smarter Sentencing Act of 2013, which would reduce some federal mandatory minimum sentences, make a modest expansion to the safety valve provision (though continuing to exclude anyone previously incarcerated in prison for more than 13 months in the past 10 years), and make the 2010 Fair Sentencing Act applicable to persons sentenced before its enactment, which would reduce sentences for people convicted of crack cocaine offenses.
THE BOTTOM LINE
A significant percentage of policy makers are reaching a consensus that our system of criminal penalties is inefficient, ineffective, and destructive and are supporting bills to change that. The results of some past reforms are bearing fruit: 2012 was the third straight year that the total number of prisoners in the U.S. decreased, shaving 27,770 prisoners off the 2011 total of 1.59 million. But few states have attempted to tackle reforms on a scale that matches the magnitude of the problem. Eric Holder has the opportunity to show some needed leadership on Monday. We hope his speech includes concrete plans for reforms that will push the envelope.
MARIJUANA LAW REFORM
All the excitment is about this: Patent Office link Published on July 16, 2013
News from the patent frontier! Liquidmetal and Apple scientists have filed a patent on "Bulk amorphous alloy sheet forming processes" by adopting a float glass process (which is nowadays used for the production of kilometers of window glass) and by optimizing it for Bulk metallic glass:
http://www.freepatentsonline.com/8485245.html
This process could enable a production of Liquidmetal on a massive scale, as stated in the patent: "A float plant, which operates non-stop for between 10-15 years, could make around 6000 kilometers of BMG glass a year in thicknesses of 0.1 mm to 25 mm, more preferably 0.4 mm to 15 mm and in widths up to 3 meters, for example"
Inventors:
Prest, Christopher D. (Cupertino, CA, US) [Apple]
Poole, Joseph C. (Cupertino, CA, US) [Apple]
Stevick, Joseph (Glendora, CA, US) [LM, PhD Cambridge]
Waniuk, Theodore Andrew (Lake Forest, CA, US) [LM]
Pham, Quoc Tran (Anaheim, CA, US) [LM]
Asignee:
Crucible Intellectual Property, LLC (Rancho Santa Margarita, CA, US)
Float plant:
Stage 1: Melting BMG
"In one embodiment of melting the feedstock include in-flight heating using, for example, induction that could momentarily raise the temperature of the BMG forming metal alloy in granular or powder form to several thousand degrees Centigrade. This method enables the instant completion of the melting process, which usually consumes a lot of energy. Specifically, granular or powder materials with pre-adjusted composition of the BMG forming metal alloy (e.g., the granular or powder material could contain elements or compounds that form the BMG forming metal alloy) could be injected into the reservoir/melter from above and the materials pass through between the induction heating coils to be instantly melted by induction heating"
Stage 2: Float Chamber
"The float glass process of the embodiments herein, for example shown in above Figure, comprises taking a molten alloy that forms a bulk-solidifying amorphous metallic glass and pouring it onto a bath of molten metal (referred to as molten bath metal to distinguish over the molten metal alloy that forms BMG), for example, a tin bath. The majority of the BMG alloys have densities in the range of 6 to 7 grams per cc. These could be zirconium based and titanium based alloys. Titanium based alloys have densities that go from about 5 to about 7 grams per cc. Tin has a density of about 7.3 grams per cc [...] So by controlling the float glass process of the embodiments herein, most of the BMG alloys should float on top of the molten tin."
"The fusible alloy of the molten bath should preferably have a higher density so that BMG alloy material would separate readily from the molten bath. One example of a fusible alloy would be a bismuth-indium-tin alloy. Bismuth would increase the density substantially over tin. Indium would also improve the density somewhat over tin. So if one would use a fused metal as the molten bath metal, which melts at approximately 60° C. and poured molten bulk amorphous alloy onto the fused metal, the molten bulk amorphous alloy would float to the top of the fused metal. In addition, the fused metal would have a relatively high thermal conductivity so one could use it to moderate the temperature of the molten bulk amorphous alloy material poured onto its surface. Since the fused metal melts at 60° C., one could even render the molten bulk amorphous alloy material poured onto it amorphous just by conduction of heat into the molten fused metal."
Stage 3: Coating
"Coatings that make profound changes in optical or electrical properties can be applied by advanced high temperature technology during the cooling of the BMG forming metal alloy in the float chamber. On-line chemical vapor deposition (CVD) of coatings can be used to lay down a variety of coatings, less than a micron thick, to reflect visible and infrared wavelengths, for instance. Multiple coatings can be deposited in the few seconds available as the BMG sheets flows beneath the coaters."
Stage 4: Annealing and/or Superplastic Forming (Optional)
"Despite the tranquility during the BMG sheet forming process using the float glass process, some stresses could develop in the BMG sheet. To relieve these stresses, the BMG sheet could undergo heat-treatment such that the heat treatment only occurs in the superplastic region of the BMG forming metal alloy without of the temperature of the BMG sheet traversing through the crystalline region of the TTT diagram of the BMG forming metal alloys, such as the time-temperature trajectories shown as (2) to (4) in FIG. 2. Also, while the temperature of the BMG sheet is in the superplastic region, one could do superplastic forming on the BMG sheet to shape the BMG sheet or form micro- and/or nano-replications on the BMG sheet. Temperatures are closely controlled both along and across the BMG sheet. One could monitor the stress levels in the BMG sheet and automatically feed back stress levels in the BMG sheet to control the temperatures during annealing and/or superplastic forming."
Stage 5: Inspection
"The float glass process of the embodiments herein could make perfectly flat, flaw-free BMG sheets. But to ensure the highest quality, inspection could take place at every stage. Automated on-line inspection could be used to reveal process faults upstream and corrected, and it enables computers downstream to steer cutters round flaws. Inspection technology could allow more than 100 million measurements a second to be made across the BMG sheet, locating flaws the unaided eye would be unable to see."
Stage 6: Marking and/or Cutting the BMG Sheet
"The BMG sheet could be marked and cut to size. In one embodiment, the certain regions of the BMG sheet could be intentionally heated using a laser and slowly cooled to allow certain precise regions to be crystallized while leaving the rest of the BMG sheet as an amorphous sheet. A diamond wheel could then be used to cut the BMG sheet with the cut traversing through the precise regions that have been crystallized while, preferably, preventing the amorphous regions of the BMG sheet from getting crystallized due to the heat generated during cutting."
Interestingly it is the first time in the latest series of patent publications, that they additionally file a set of tough iron-based BMG`s, which are referenced to Demetriou and Johnson: "TOUGH IRON-BASED BULK METALLIC GLASS ALLOYS" http://www.freepatentsonline.com/y2010/0300148.html
Good Evening from Bull Warrior Stocks,
The time is here! Real quick though, two important things.
1) Our last Solo Warrior Chart selection from two weeks ago turned out to be an absolute bull chart monster with +160% gains in only five days. Read all about it here. Because of this success, we have decided to bring back this strategy again.
2) This chart set-up follows one that we've done a free video lesson on entitled "Hammer Time". It is one of our favorite technical chart pattern set-ups, so if you've never watched this free video lesson before, you can watch it here. We'd highly recommend you as that will make this alert that much more clear and easy to understand.
With these two important points out of the way, let's jump into breaking down this week's Solo Warrior Chart.
PSID currently is displaying one of our favorite bottom bounce chart pattern set-ups. How important and worthwhile do we feel this set-up is? Enough so to do a complete video lesson on it! (take the hint... if you haven't watched it, make sure to go up above and click that link!)
We'll be the first to admit, it takes more then simply a Hammer Candlestick formation to qualify for this pattern, but as we're about to show you in the analysis, there are many other factors that help to build the confidence and bullish feelings towards this one.
As is the case with any bottom bounce chart set-up, there is always massive upside potential, but again, there are OTHER things that need to be factored in. In particular, what is the volume doing and what kind of previous history does that chart have?
Check out the chart below, and then be sure to scroll down past it to get the meat and potatoes of our analysis and the answers to the above questions.
We'll start out with the obvious. Look at that beautiful Hammer Candlestick. At one point during Friday the chart wasn't looking so good because that candle was all solid red...BUT, by the time the closing bell came around, the Bulls had fought back from the bottom and almost closed even on the day. While it did close red, the important part was how the Bulls came to life and pushed back up giving us the Hammer Candle. If this fighting by the Bulls continues into this week, the action should get very fun for everyone (except any shorts).
A Hammer Candle alone is only a portion of the set-up though. If it occurs on larger than average volume, that makes it even a more powerful set-up... and as you can see above, the volume was undoubtedly higher than the average. This brings about the question: do we have a capitulation on our hands? If indeed we do and the Bulls keep on pushing... lookout!
Things brings up an important point though. Just because there is big volume doesn't mean capitulation! Case in point, look back at the day we have marked where that massive volume bar was. If all you looked at was the volume, it would be very misleading, because you must also look at the type of candlestick formed. In this case, it was not a bullish candlestick in the least. In fact, it was basically a total solid red candlestick which is the worst kind.
Why bring this up? Because it is important to understand that PSID's current set-up "has" a bullish candlestick to go along with the above average volume on Friday.
Looking back even further into the chart, you can see another above average volume day. When you look at the candlestick, you can see it was a Spinning Top. Although it has a different appearance compared to the Hammer Candle, the "meaning" is the same: potential bottom! Sure enough, after this candlestick and large volume, the stock made a very solid bounce of +58% in a very short amount of time.
Not only does this provide a great example of why you need BOTH a bullish candle and high volume, but it also shows that PSID has a past history of big bounces. As I've said in other alerts, a previous history is not "needed" in order for a future bounce to happen...HOWEVER, it sure does make us feel better knowing that the chart ALREADY has that potential to bounce.
There are two areas of resistance that lie ahead worth noting, but after those two, that is where the price could really get moving as there is a big "space" in resistances. The first level that needs to be broken is at $.11. After this, $.14 is next... after this, there is nothing until the 50-SMA, and as you can see on the chart, this is quite a ways away from $.14.
With all this being said, resistances can be minor worries in regards to a bottom bounce chart. When charts bounce, shorts begin to cover and other buyer's pile in, so these resistances become futile. They are still helpful though in the sense that they make "measuring-the-strength" of the bounce easier.
We started on this point, and it's a great place to end. We talked about how the Bulls really began to fight back and that's what caused the Hammer Candle to form. But "when" did this fight take place? Was it early in the day and then the chart went quiet the remainder of the time?
Below we have put a 60-minute chart (each candlestick represent 60 minutes of time) and as you can see, the Bulls showed back up in the last two hours of the day, but especially in that final hour! Who knows... if the closing bell wouldn't have rang, the price might have kept getting pushed further up. Because of this, it would not be shocking in the least to see the Bulls come firing out of the gates on Monday morning.
For those of you in the community who also like to have some fundamental information on top of the technical chart information, no worries, we've got you covered! If you like to know about more then just the chart, keep on reading...
PSID is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. The company is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
In May 2011, PSID acquired California-based MicroFluidic Systems (MFS), founded in 2001, which specializes in the development and production of automated instruments for detecting and processing biological samples. MFS' core technology is used for airborne pathogen detection, rapid clinical diagnostics and sample preparation applications.
MFS' microfluidic technology alleviates all existing problems by replacing robotics with integrated microfluidics, reducing cost and increasing reliability. Its microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed, automated system. The embedded devices perform cell lysis (including difficult spores) in less than one minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.
The management team at PSID is pretty darn impressive. You can read all about them here. Along with this, you can tell they take pride in communicating with their investor's and in ensuring all questions are answered. Many frequently asked questions and answers can be found here. As far as press releases and SEC filings go... again... it is very evident the company cares about their communication. Click here for all the latest new releases and filings.
If you love bounces with big upside potential and a previous history of making bullish bounces, then PSID should be atop your radar Monday and this week. If you missed out on our last Solo Warrior Chart that exploded to triple digit gains, then be sure not to miss this one!
As we always remind you, remember, be disciplined, follow your trading rules, use stop losses, and do-not-be-greedy.
Just received this in my email at 6:33 pm 7/14/13
The fact is MJNA is a subsidiary holdings company (CanChew Gum, Canchew, Biotechnologies, Canipa Holdings, KannaLife Sciences, HempMeds RX, Phytosphere, Red Dice Holdings, Wellness Managed Services) is MJNA.
Like a portfolio of stocks the portfolio of MJNA's holdings will directly effect MJNA's bottom line. They are dependent on each others success. To isolate one (Dixie) from effecting MJNA's bottom line is a fallacy.
When one subsidiary holding is mentioned in the same sentence, such as ArcView and Dixie, to suggest that MJNA isn't part of the equation is naive and foolish. GL
With the long weekend, Friday will be dead, selling by Wednesday might be a good idea but I rode MDBX for 3 days the first time before I bailed. Just watch the charts and remember to use stop sells.
OMGosh....It looks like we have another MDBX on our hands here. The float is so low this thing will explode. Catch it while you can. Tomorrow I'm buying.
The simple matter of MJNA refiling, restatement and or correcting past filings is about a pink sheet wanting to up list. As pinkies go they pretty much do and say what they want. BUT. MJNA wants more for its self and that is made plain by it taking these steps. This is a true positive and reflects well of the company and will further benefit investor shareholders. GO MJNA AWAY!
That is not true. If it closes below .10 the up-listing won't happen but if it dips below .10 and closes above .10 it still qualifies for up-listing.
Innovative Technology Company Invents Real “Star Trek” Medical Scanner That Diagnoses Patient Health in Seconds.
MAYBE you’re old enough to remember Dr. Leonard “Bones” McCoy, the surgeon on board the U.S.S. Enterprise starship from the original “Star Trek” program.
During a mission, when a crew member was ill, Dr. McCoy used a “tricorder” – a tiny handheld medical diagnostic instrument – to read the patient’s vital signs in seconds. And he didn’t have to take a blood sample or puncture the skin with a needle to do it.
Well, now a technology company that recently went public – Biozoom, Inc. (BIZM) www.biozoom.net – has developed a real-life tricorder: the Biozoom Biofeedback Scanner.
It’s the only handheld diagnostic device of its kind worldwide that tests for your health without blood tests or piercing your skin.
But the Biozoom Scanner, developed in partnership with Carl Zeiss and Vodafone, isn’t science fiction. It exists now, and has already been successfully tested on 1,200 patients. Units have been used by doctors in hospital settings – and will soon be available to other health care professionals and the general public.
That means you’ll be able to monitor your blood chemistry at home – in seconds – without having your blood drawn through a needle at a diagnostic lab, and then waiting 3 to 5 days for the outcome. Or paying a big lab bill.
Is It The Tech Stock That Will Change The Healthcare Paradigm?
Biozoom analysis takes only 16 milliseconds, and it’s completely noninvasive. A beam of light detects and measures antioxidant levels … vitamins … free radicals … and cyotochrom oxidase, a critical enzyme that aids in the production of energy in your cells. Planned upgrades will allow measurement of BAC, fat lipids, venous insufficiency, blood pressure, smoke poisoning, oxygen saturation HbO2, and even blood sugar levels – an essential daily test for diabetics that currently requires piercing the skin with a sharp needle. The cost of treating diabetes in the United States is $220 billion a year.
Why Is The Home Health Diagnostic Market So Hot?
One factor fueling the demand for home health tests is the lagging economy, which has left millions of Americans without health plan coverage to pay for medical laboratory tests. Bloomberg reports that the do-it-yourself home health test market, estimated at $2 billion to $3 billion globally, is growing by 20% a year.
Medical devices account for 6% of U.S. health care spending. In 2010, the last year studied, spending on medical devices and in-vitro diagnostics totaled $156.3 billion. The global home healthcare device industry is expected to reach $29 billion in 2017.
Biozoom’s invention could grab significant market share in this rapidly growing segment.
Cutting-edge Medical Optics
The core technology behind Biozoom is its proprietary analysis methodology and the cutting-edge optics designed by Carl Zeiss, a global titan in optical engineering. Biozoom (BIZM) has the right to use the Carl Zeiss name in its marketing, which adds instant credibility to the product.
In essence, the Biozoom Scanner is a spectrophotometer, meaning it identifies substances by the unique spectrum they reflect. The device radiates light into the skin using specially developed LEDs, and the light spectrum reflected from the skin contains spectroscopic information – which is absorbed by a photo-detector and analyzed using a proprietary Biozoom analysis methodology.
Subscription-Based Business Model
Biozoom’s subscription-based model gives it two core revenue streams. The company makes money from the sale of the handheld device, expected to retail for around $200. The second income stream is recurring monthly revenue from a subscription to the Biozoom analysis methodology for providing biometric read-outs and health advice based on the outcome.
Hold Better Health In The Palm Of Your Hand
The low-hanging fruit for Biozoom (BIZM) is in wellness applications. In a test of 50 students, 20% of the students stopped cigarette use after using the device – and 83% increased their levels of antioxidants after 2 months.
The versatility of the Biozoom Scanner gives it broad applicability, including 29,960 health clubs in the U.S., corporate wellness programs, and the spa industry.
There are even applications outside of health, wellness, and beauty. In the near future, both law enforcement officers and drivers will be able to use the Biozoom Scanner to measure blood BAC levels. The Biozoom spectrometer can also be used to measure components of car and truck emissions, meaning potential partnerships within the automotive industry.
Biozoom’s Nanotechnology Future
The company’s R&D laboratory is developing its next-generation biomarker scanner, a chip-sized version of the Biozoom spectrometer. A major application for the miniaturized version is integration into smart phones, laptops and tablets. The nanospectrometer could even be integrated into consumer devices such as toothbrushes, electric razors, hair dryers or cosmetics cases.
The Physician’s Friend
Physicians and other health care professionals can eliminate lab delays and costs for their patients by taking biomarker readings in their office during exams with the Biozoom Scanner. In 2012, there were 834,769 active physicians in the U.S. and 18,000 hospitals worldwide. Use of the Biozoom Scanner will provide the ability to scan patients, instantly have feedback, and apply the knowledge to health, fitness and lifestyle adjustments and goals.
Partnering For Distribution
Biozoom (BIZM) isn’t just going to sell scanners to consumers and physicians. The company has plans to actively pursue partnerships with major corporations in a position to benefit from use of the Biozoom Scanner. These include companies like Nutrilite, GNC, CVS, NuSkin, Neuform, P&G, Wal-mart, Walgreens, Target, Media Mart, and Rossman.
Multimillion-Dollar IP Portfolio
Biozoom (BIZM) has filed 19 patents in such areas as optics, temperature drift, database management, nanospectroscopy, fuel consumption, fitness enzymes, and others. As such, its portfolio of intellectual property is expected to become a multimillion-dollar asset with huge income potential should the company decide to license some of its technology innovations.
The Future Of Health Care And Self-Care
Given Biozoom’s incredible advancements in nano-optics, it’s only a matter of time before analysts and the mainstream media get wind of the story. The company will not fly under the radar of Wall Street gurus for long.
It’s difficult to put a ceiling on the growth of a technology company with a cutting-edge technology, especially in the booming healthcare sector.
The company could grow to the point where Biozoom absolutely dominates the biometric device niche – or they might become a prime target for an industry giant to acquire. Either way, Biozoom (BIZM) could be one of the best tech stocks for 2013 and beyond.
Correct. You hit the nail on the head DocK. Its open season to sell the CBD products every where without prohibitive restrictions. While most are waiting for mj to become legal the CBD arena is where the revenues are now available to sift. If Canchew gum is making progress those revenues will find their way into CANV to help alleviate some of the conjecture about the direness of the CANV deal. If their previously spoken of units sold is true then they have already brought in a $750,00 in just 2 months time or less. IMHO GO MJNA GO Longs.
My one post for the day.
It appears true that direct application of cannabinoids (CBD) to the cancer is the surest course to its eradication. The following video gives a glimpse of its value and application through the lives of others.
The following presentation of RUN FROM THE CURE: The Rick Simpson Story was made possible by Rick Simpson and video producer Christian Laurette... made for free to teach YOU how to heal yourself of disease and illness using cannabinoids. Comments will be moderated to protect those who need this information. We are not asking anyone if it works, we are telling you it works; it is not a debate. Too many uneducated people coming to this channel to speak their mind on a life-saving plant they know nothing about and giving bad advice and in many cases
I also ordered and live in Florida:
Instructions
Please keep a printed copy of this order for your records.
The bill will appear on your credit card as: The Hemp Network
Order Information Order ID: CBD-201305241357-255618
Order Date: 24 MAY 2013 13:57:26
Item Quantity Description Discount Amount Refunded
CG-32 1 CanChew Gum 32 pack. 125.00
Subtotal 125.00
Tax Rate 0.00%
Tax 0.00
Shipping/Handling 8.95
Total $133.95
Return Policy
CanChew Gum Marketing Group takes many measures to ensure the quality of the product is the best it can be, however due to the nature of the product we cannot accept returns on the product. The purchaser agrees that all sales are final with the exception of future shipments in our Consumer Benefit Program which can be cancelled at any time prior to the automatic shipment leaving our warehouse.
Contact Information
Canchew Gum Marketing Group Customer Service
sales@canchewgum.com
858-304-1549
Will inform all here of my findings when the time comes.
40,000 investors times $125.00 PER UNIT = $5 million to MJNA
Help yourself and your investment. Buy CanChew Gum. GO $MJNA
I ordered the gum today to see for myself its efficacy. It's mind boggling the amount of revenue potential this product can possibly bring in. If you combine the whole seller end and retail buyer end into total potential revenue generated and accept for fact that 3000 orders have been filled and another 3000 are preparing for shipment in just 2 months time or less, we are talking 2.6mm in revenue this year alone at a minimum. And this is just getting off the ground. This is just one product, also. Things are getting very interesting to say the least.
COLGATE (silicon dioxide, sodium fluoride, and triclosan) paste
dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c19f549-b64b...?
COLGATE (silicon dioxide, sodium fluoride, and triclosan) paste, dentifrice ... between teeth. These may be signs of periodontitis, a serious form of gum disease.
Patent US4140757 - Extension of gum thickener with silicon dioxide ...
www.google.com/patents/US4140757?
The extension of a gum thickener in a dentifrice composition of high water content is achieved by replacement of up to 50% of the gum thickener with a silica ...
Seems that the mmj and mj change in momentum for decriminalization is picking up speed. We may see changes at the Federal level much sooner than the estimates in which case we will experience a huge gap up when it does. GO LONGS GO $MJNA
Many new shareholders (of the 40k current MJNA) are advised by their brokers to expaned their long term investments to include mj sector stocks.
Tripp is right here.... Tripp Keber
You mean a fair post? Its still none the less sexist.
Having it for one. Filing incomplete like they did, did nothing for their credibility and competency.
Exactly correct. We must really annoy management with all the child like whining.
That info would have done the pps a whole lot better had it been include at the initial release today.
I understand your misgivings about the companies approach to this embryonic industry but, the mechanics to penetrate this environment necessitates the the measures that management are utilizing. If there was a change in the classification of mj with the FEDS they would be using a more fundamental (bank loan) approach. Hang in there. Give it time.
Patch Adams, MD, commenting on the medical value of marijuana said: “The medical use of marijuana is ancient and well-documented. Illegality has inhibited research on this drug which is a better medication than many pharmaceutical drugs. The idea that someone can go to jail for marijuana is a mockery of justice.”
Link
I don't agree or disagree with your math. If being short sighted suits you before taking the plunge to invest in this epic company (MJNA) then follow your forte. I prefer to look at the future possibilities. This is the ground floor opportunity for those with vision.
Live and learn, hopefully. GO MJNA
Thank-you. But I have been here so long I know who to trust and not trust. I've just been to busy today to keep up with the members. And as far as the report, I went straight to the numbers, and smiled. GO $MJNA and GO LONGS
Is DTC chill confirmed removed?
I like it. More transparency. Slowly coming clean on a few things. GO MJNA and GO LONGS.
Holy crap..numbers are huge!!!